A Phase 3 interventional study of TQC3721 Suspension for inhalation and Placebo of TQC3721 Suspension for Inhalation in Chronic Obstructive Pulmonary Disease, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Not yet recruiting at 76 sites in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-10.
Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited — 2 open to participants now, 6 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sino Biopharmaceutical Limited.
Among the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, this one is the 2nd largest by planned enrollment, is one of 5 that started in 2025, is one of 2 in phase 3, and was the 13th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 40–80
By country, each count listing its studies:
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 5 started in 2025.
This study's planned enrollment of 666 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 113 across the 17 interventional studies. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Chia Tai Tianqing Pharmaceutical Group Co., Ltd., one of the names counted as Sino Biopharmaceutical Limited. Under that name alone:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.
4 of the studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07464587Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | 2027-02 |
| NCT07147946Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | 2027-03 |
| NCT06707883Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | 2026-12 |
| NCT06789289Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | 2027-03-17 |
Add all 4 to your calendar (.ics) → With an account.
Among the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
11.Previously received TQC3721 treatment. 12.Patients who received therapy within 4 weeks prior to the screening period 13.In the investigator's assessment, patients are unable to discontinue the prohibited drugs specified in the protocol during the screening and treatment phases of the study; 14.Patients with a history of uncontrolled current diseases that the investigator judges to be clinically significant; 15.A history or current evidence of clinically significant cardiovascular or cerebrovascular diseases; 16.A history of malignant tumors (cured or uncured) in any organ or system within the past 5 years; 17.Intolerance or allergy to salbutamol or other inhaled bronchodilator therapies for COPD; 18.Patients requiring long-term oxygen therapy; 19.Female subjects who are currently pregnant, breastfeeding, or planning to become pregnant during the study period after enrollment; 20.Having participated in any clinical trial of drugs or medical devices within 4 weeks or 5 half-lives (whichever is longer) prior to the screening visit; 21.Other conditions deemed unsuitable for participation in the study by the investigator.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inhalation of TQC3721 suspension (6mg/2ml), one unit dose twice daily for 24 weeks
Drug: TQC3721 Suspension for inhalation
Inhalation of TQC3721 placebo, one unit dose twice daily for 24 weeks
Drug: Placebo of TQC3721 Suspension for Inhalation
TQC3721 suspension for inhalation is a Phosphodiesterase3/4 (PDE3/4) inhibitor
Placebo without drug substance
Mean change in the area under the curve (AUC) of Forced Expiratory Volume in 1 second (FEV1)
Change from baseline in mean FEV1 AUC over 0-12 hours after 12 weeks of treatment.
Time frame: Baseline to 12 weeks after treatment
Changes in peak FEV1 value
Changes from baseline in peak FEV1 within 4 hours after morning dosing at Weeks 6, 12, and 24 of treatment.
Time frame: Baseline to 6 weeks, 12 weeks, 24 weeks after treatment
Changes in trough FEV1 values
Changes from baseline in morning trough FEV1 at Weeks 6, 12, and 24 of treatment.
Time frame: Baseline to 6 weeks, 12 weeks, 24 weeks after treatment
Average FEV1 AUC 0-4h
Change from baseline in the average FEV1 AUC 0-4h within 4 hours after morning dosing at 6, 12, and 24 weeks of treatment.
Time frame: Baseline to 6 weeks, 12 weeks, 24 weeks after treatment
St. George's Respiratory Questionnaire
Changes in St. George's Respiratory Questionnaire (SGRQ) total scores from baseline at 6, 12, and 24 weeks of treatment.
Time frame: Baseline to 6 weeks, 12 weeks, 24 weeks after treatment
Chronic Obstructive Pulmonary Disease Assessment Test
Self-assessment for Patients with COPD:Numbers 0 to 5 indicate the severity (with 0 being the mildest and 5 being the most severe).
Time frame: At 6 weeks, 12 weeks, and 24 weeks of treatment
Average FEV1 AUC (6-12h)
Change from baseline in mean FEV₁ AUC (6-12 h) at Week 12 following dosing.
Time frame: Baseline to 12 weeks after treatment
Annual rate of acute exacerbation of COPD
The annualized rate of acute exacerbation of moderate/severe COPD after 24 weeks of treatment.
Time frame: Baseline to 24 weeks after treatment
Time of first acute exacerbation of moderate/severe COPD
The time of the first acute exacerbation of moderate/severe COPD within 24 weeks of treatment.
Time frame: Baseline to 24 weeks after treatment
Adverse event (AE)
The number of participants with AEs, serious dverse event (SAEs), drug-related AEs, and abnormal lab results.
Time frame: D-28 to within 25 weeks of treatment
Assessment of respiratory symptoms in COPD
Change from baseline in weekly mean Evaluating Respiratory Symptoms in COPD total score
Time frame: Baseline to 6 weeks, 12 weeks, 24 weeks after treatment
Transition Dyspnea Index (TDI) score
Change in Transition Dyspnea Index (TDI) score relative to Baseline Dyspnea Index (BDI) score
Time frame: Baseline to 6 weeks, 12 weeks, 24 weeks after treatment
Chronic Obstructive Pulmonary Disease Assessment Test (CAT) score
Change in Chronic Obstructive Pulmonary Disease Assessment Test (CAT) score from baseline
Time frame: Baseline to 6 weeks, 12 weeks, 24 weeks after treatment
Change from baseline in rescue medication use
Changes from baseline in rescue medication use during treatment at Weeks 6, 12, and 24 versus the placebo group
Time frame: Baseline to 6 weeks, 12 weeks, 24 weeks after treatment.
Interleukin-6 (IL-6), Interleukin-8 (IL-8), and C-reactive protein (CRP) at Week 12 and Week 24
IL-6, IL-8, and C-reactive protein (CRP) at Week 12 and Week 24. The elevated serum C-reactive protein (CRP) levels in patients with chronic obstructive pulmonary disease (COPD) are primarily associated with pulmonary inflammatory responses.
Time frame: At Week 12 and Week 24
Plasma drug peak concentration
Perform Pharmacokinetics (PK) analysis of TQC3721 blood drug concentration data at baseline, week 6, and week 12 to evaluate the PK characteristics of TQC3721 in COPD patients.
Time frame: Day 1: 0.5 hour after-dose, Week 6: 1 hour pre-dose, 0.5 hour after-dose; Week 12: 1 hour pre-dose, 0.5 hour after-dose
Start is estimated for Sep 2025; primary completion for Mar 2027, 18 months later.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's planned 18 months is close to that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TQC3721
Pulmonary Disease, Chronic Obstructive →
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. →